| Literature DB >> 29868791 |
Liang Li1, Wessam Abdelhady1, Niles P Donegan2, Kati Seidl3, Ambrose Cheung2, Yu-Feng Zhou1,4, Michael R Yeaman1,5, Arnold S Bayer1,5, Yan Q Xiong1,5.
Abstract
Persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia (PB) represents an important subset of S. aureus endovascular infections. In this study, we investigated potential genetic mechanisms underlying the persistent outcomes. Compared with resolving bacteremia (RB) isolates (defined as isolates associated with negative results of blood cultures 2-4 days after initiation of therapy), PB strains (defined as isolates associated with positive results of blood cultures ≥7 days after initiation of therapy) had significantly earlier onset activation of key virulence regulons and structural genes (eg, sigB, sarA, sae, and cap5), higher expression of purine biosynthesis genes (eg, purF), and faster growth rates, with earlier entrance into stationary phase. Importantly, an isogenic strain set featuring a wild-type MRSA isolate, a purF mutant strain, and a purF-complemented strain and use of strategic purine biosynthesis inhibitors implicated a causal relationship between purine biosynthesis and the in vivo persistent outcomes. These observations suggest that purine biosynthesis plays a key role in the outcome of PB and may represent a new target for enhanced efficacy in treating life-threatening MRSA infections.Entities:
Mesh：
Substances：
Year: 2018 PMID： 29868791 PMCID： PMC6151072 DOI： 10.1093/infdis/jiy340
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226